Liquidia Corporation
LQDA | NASDAQ
$66.43
-$0.45 (-0.67%)
At close: Sep 21, 2026, 4:00 PM ET
$66.44
+$0.01 (+0.02%)
Pre-market:
Sep 22, 2026, 6:06 AM ET
Company Profile
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Key Executives
| Name | Position |
|---|---|
| Roger A. Jeffs | Chief Executive Officer & Director |
| Michael Kaseta | Chief Operating Officer & Chief Financial Officer |
| Christian Perez Font | Senior Vice President, Chief Compliance Officer & Associate General Counsel |
| Dana Boyle | Chief Accounting Officer |
| Matt Snow | Senior Vice President of Sales |
| Michael Post | Senior Vice President of Marketing |
| Rajeev Saggar | Chief Medical Officer |
| Russell Schundler | General Counsel & Corporate Secretary |
| Sarah Krepp SPHR | Chief Human Resources Officer |
| Scott Moomaw | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Sep 03, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 12, 2026 | 8-K | Current Report |
| Aug 04, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 29, 2026 | 4 | Filing |
Liquidia Corporation
| Country | United States |
| IPO Date | Jul 25, 2018 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 216 |
| CEO | Roger A. Jeffs |
Contact Details
419 Davis Drive Morrisville,
North Carolina 27560 United States
Stock Details
| Ticker Symbol | LQDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819576 |
| CUSIP Number | 53635D202 |
| ISIN Number | US53635D2027 |
| SIC Code | 2834 |
Recent News
- 7 days ago / defenseworld.netCalifornia State Teachers Retirement System Acquires 5,835,156 Shares of Liquidia Corporation $LQDA
- 11 days ago / zacks.comLQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
- 12 days ago / zacks.comCan a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
- 20 days ago / globenewswire.comLiquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
- 21 days ago / globenewswire.comLiquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
- 22 days ago / zacks.comCan LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
- 22 days ago / zacks.comIs the Options Market Predicting a Spike in Liquidia Stock?
- 25 days ago / gurufocus.comLiquidia Corp (LQDA) Stock Down 3.1% -- Now Undervalued? GF Score: 70/100
- 25 days ago / seekingalpha.comLiquidia: A Linear Launch Priced For Exponential Growth
- 26 days ago / zacks.comLiquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Add to Watchlist
Select watchlists to add or remove LQDA